{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T19:33:21Z","timestamp":1776454401516,"version":"3.51.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["702108"],"award-info":[{"award-number":["702108"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008468","name":"Canadian Urological Association","doi-asserted-by":"publisher","award":["2017-2018"],"award-info":[{"award-number":["2017-2018"]}],"id":[{"id":"10.13039\/100008468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000109","name":"Prostate Cancer Canada","doi-asserted-by":"publisher","award":["D2013-17"],"award-info":[{"award-number":["D2013-17"]}],"id":[{"id":"10.13039\/501100000109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41391-025-00964-x","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T15:47:00Z","timestamp":1744040820000},"page":"953-959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The association between statin use, genetic variation, and prostate cancer risk"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8602-9052","authenticated-orcid":false,"given":"Ali","family":"Amiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qihuang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae H.","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-6419","authenticated-orcid":false,"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil E.","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Finelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6715-5934","authenticated-orcid":false,"given":"Robert J.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"964_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"964_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403:1683\u2013722.","journal-title":"Lancet"},{"key":"964_CR3","unstructured":"Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M, et al. Cancer tomorrow. 2021. Global Cancer Observatory: cancer today. Lyon: International Agency for Research on Cancer; 2020."},{"key":"964_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 Update on prostate cancer epidemiology and risk factors\u2014a systematic review. Eur Urol. 2023;84:191\u2013206.","journal-title":"Eur Urol"},{"key":"964_CR5","first-page":"219","volume":"9","author":"X Ding","year":"2019","unstructured":"Ding X, Zhang W, Li S, Yang H. The role of cholesterol metabolism in cancer. Am J Cancer Res. 2019;9:219.","journal-title":"Am J Cancer Res"},{"key":"964_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.5306\/wjco.v11.i8.573","volume":"11","author":"CI Barbalata","year":"2020","unstructured":"Barbalata CI, Tefas LR, Achim M, Tomuta I, Porfire AS. Statins in risk-reduction and treatment of cancer. World J Clin Oncol. 2020;11:573.","journal-title":"World J Clin Oncol"},{"key":"964_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrurol.2016.199","volume":"14","author":"MA Alfaqih","year":"2017","unstructured":"Alfaqih MA, Allott EH, Hamilton RJ, Freeman MR, Freedland SJ. The current evidence on statin use and prostate cancer prevention: are we there yet? Nat Rev Urol. 2017;14:107\u201319.","journal-title":"Nat Rev Urol"},{"key":"964_CR8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.eururo.2020.12.031","volume":"79","author":"RJ Hamilton","year":"2021","unstructured":"Hamilton RJ, Ding K, Crook JM, O\u2019Callaghan CJ, Higano CS, Dearnaley DP, et al. The association between statin use and outcomes in patients initiating androgen deprivation therapy. Eur Urol. 2021;79:446\u201352.","journal-title":"Eur Urol"},{"key":"964_CR9","doi-asserted-by":"publisher","first-page":"e2242676","DOI":"10.1001\/jamanetworkopen.2022.42676","volume":"5","author":"VH Jayalath","year":"2022","unstructured":"Jayalath VH, Clark R, Lajkosz K, Fazelzad R, Fleshner NE, Klotz LH, et al. Statin use and survival among men receiving androgen-ablative therapies for advanced prostate cancer: a systematic review and meta-analysis. JAMA Netw open. 2022;5:e2242676.","journal-title":"JAMA Netw open"},{"key":"964_CR10","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1158\/1055-9965.EPI-19-0464","volume":"28","author":"CH Righolt","year":"2019","unstructured":"Righolt CH, Bisewski R, Mahmud SM. Statin use and prostate cancer incidence in Manitoba, Canada: a population-based nested case\u2013control study. Cancer Epidemiol Biomark Prev. 2019;28:1765\u20138.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"964_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/ijc.31295","volume":"143","author":"DE Dawe","year":"2018","unstructured":"Dawe DE, Ye X, Czaykowski P, Jassal D, Singh H, Skarsgard D, et al. The effect of statin use on the incidence of prostate cancer: a population-based nested case\u2013control study. Int J Cancer. 2018;143:190\u20138.","journal-title":"Int J Cancer"},{"key":"964_CR12","doi-asserted-by":"publisher","first-page":"7399","DOI":"10.1002\/cam4.2500","volume":"8","author":"K Wang","year":"2019","unstructured":"Wang K, Gerke TA, Chen X, Prosperi M. Association of statin use with risk of Gleason score-specific prostate cancer: a hospital-based cohort study. Cancer Med. 2019;8:7399\u2013407.","journal-title":"Cancer Med"},{"key":"964_CR13","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/07853890.2020.1800074","volume":"52","author":"N Ahangari","year":"2020","unstructured":"Ahangari N, Doosti M, Ghayour Mobarhan M, Sahebkar A, Ferns GA, Pasdar A. Personalised medicine in hypercholesterolaemia: The role of pharmacogenetics in statin therapy. Ann Med. 2020;52:462\u201370.","journal-title":"Ann Med"},{"key":"964_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cpt.2557","volume":"111","author":"RM Cooper-DeHoff","year":"2022","unstructured":"Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin Pharm Ther. 2022;111:1007\u201321.","journal-title":"Clin Pharm Ther"},{"key":"964_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41391-020-0238-y","volume":"24","author":"MJ Lee","year":"2021","unstructured":"Lee MJ, Jayalath VH, Xu W, Lu L, Freedland SJ, Fleshner NE, et al. Association between metformin medication, genetic variation and prostate cancer risk. Prostate Cancer Prostatic Dis. 2021;24:96\u2013105.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"964_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/aje\/kwp398","volume":"171","author":"GM Clarke","year":"2010","unstructured":"Clarke GM, Morris AP. A comparison of sample size and power in case-only association studies of gene-environment interaction. Am J Epidemiol. 2010;171:498\u2013505.","journal-title":"Am J Epidemiol"},{"key":"964_CR17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/ng.882","volume":"43","author":"Z Kote-Jarai","year":"2011","unstructured":"Kote-Jarai Z, Olama AAA, Giles GG, Severi G, Schleutker J, Weischer M, et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet. 2011;43:785\u201391.","journal-title":"Nat Genet"},{"key":"964_CR18","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1158\/1055-9965.EPI-08-0317","volume":"17","author":"Z Kote-Jarai","year":"2008","unstructured":"Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomark Prev. 2008;17:2052\u201361.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"964_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/srep24521","volume":"6","author":"P Tan","year":"2016","unstructured":"Tan P, Wei S, Tang Z, Gao L, Zhang C, Nie P, et al. LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies. Sci Rep. 2016;6.24521.","journal-title":"Sci Rep"},{"key":"964_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/COC.0000000000001012","volume":"46","author":"Z Cao","year":"2023","unstructured":"Cao Z, Yao J, He Y, Lou D, Huang J, Zhang Y, et al. Association between statin exposure and incidence and prognosis of prostate cancer: a meta-analysis based on observational studies. Am J Clin Oncol. 2023;46:323\u201334.","journal-title":"Am J Clin Oncol"},{"key":"964_CR21","doi-asserted-by":"publisher","first-page":"666","DOI":"10.4103\/1008-682X.190327","volume":"19","author":"P Tan","year":"2017","unstructured":"Tan P, Zhang C, Wei S-Y, Tang Z, Gao L, Yang L, et al. Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review. Asian J Androl. 2017;19:666\u201371.","journal-title":"Asian J Androl"},{"key":"964_CR22","doi-asserted-by":"crossref","unstructured":"Chavarriaga J, Penn LZ, Khurram N, Lajkosz K, Longo J, Chen E, et al. Statin concentration in prostatic tissue is subtype-and dose-dependent. Urology. 2024;194:172\u20139.","DOI":"10.1016\/j.urology.2024.08.059"},{"key":"964_CR23","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-19-2853","volume":"26","author":"EH Allott","year":"2020","unstructured":"Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, et al. Statin use is associated with lower risk of PTEN-null and lethal prostate cancer. Clin Cancer Res. 2020;26:1086\u201393.","journal-title":"Clin Cancer Res"},{"key":"964_CR24","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41391-022-00554-1","volume":"25","author":"EL Craig","year":"2022","unstructured":"Craig EL, Stopsack KH, Evergren E, Penn LZ, Freedland SJ, Hamilton RJ, et al. Statins and prostate cancer\u2014hype or hope? The epidemiological perspective. Prostate cancer prostatic Dis. 2022;25:641\u20139.","journal-title":"Prostate cancer prostatic Dis"},{"key":"964_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/17425255.2021.1876661","volume":"17","author":"H Bruckmueller","year":"2021","unstructured":"Bruckmueller H, Cascorbi I. ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding? Expert Opin Drug Metab Toxicol. 2021;17:369\u201396.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"964_CR26","doi-asserted-by":"crossref","unstructured":"Sarwar S, Morozov VM, Newcomb MA, Yan B, Brant JO, Opavsky R, et al. Overcoming ABCB1 mediated multidrug resistance in castration resistant prostate cancer. Cell Death Dis. 2024;15:558.","DOI":"10.1038\/s41419-024-06949-3"},{"key":"964_CR27","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/pros.23137","volume":"76","author":"OF Karatas","year":"2016","unstructured":"Karatas OF, Guzel E, Duz MB, Ittmann M, Ozen M. The role of ATP-binding cassette transporter genes in the progression of prostate cancer. Prostate. 2016;76:434\u201344.","journal-title":"Prostate"},{"key":"964_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.869461","volume":"13","author":"TS Lima","year":"2022","unstructured":"Lima TS, Souza LO, Iglesias-Gato D, Elversang J, J\u00f8rgensen FS, Kallunki T, et al. Itraconazole reverts ABCB1-mediated docetaxel resistance in prostate cancer. Front Pharmacol. 2022;13.869461.","journal-title":"Front Pharmacol"},{"key":"964_CR29","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1097\/JTO.0000000000000262","volume":"9","author":"JL Weissfeld","year":"2014","unstructured":"Weissfeld JL, Diergaarde B, Nukui T, Buch S, Pennathur A, Socinski MA, et al. Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III\u2013IV lung cancer. J Thorac Oncol. 2014;9:1264\u201371.","journal-title":"J Thorac Oncol"},{"key":"964_CR30","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jmoldx.2014.11.005","volume":"17","author":"VM Pratt","year":"2015","unstructured":"Pratt VM, Beyer BN, Koller DL, Skaar TC, Flockhart DA, Levy KD, et al. Report of new haplotype for ABCC2 gene: rs17222723 and rs8187718 in cis. J Mol Diagn. 2015;17:201\u20135.","journal-title":"J Mol Diagn"},{"key":"964_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-019-1847-4","volume":"20","author":"H Lin","year":"2019","unstructured":"Lin H, Hargreaves KA, Li R, Reiter JL, Wang Y, Mort M, et al. RegSNPs-intron: a computational framework for predicting pathogenic impact of intronic single nucleotide variants. Genome Biol. 2019;20:1\u201316.","journal-title":"Genome Biol"},{"key":"964_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01508-0","volume":"24","author":"L Sun","year":"2022","unstructured":"Sun L, Ding H, Jia Y, Shi M, Guo D, Yang P, et al. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer. Breast Cancer Res. 2022;24.12.","journal-title":"Breast Cancer Res"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00964-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00964-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00964-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T02:47:58Z","timestamp":1764038878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00964-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["964"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-00964-x","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the University Health Network Research Ethics Board (REB#13-6476). All participants signed a written informed consent prior to entering the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}